By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has acquired certain assets from Perlegen Sciences, which ceased operations late last year.

Australia's Genetic Technologies said that the primary asset it has obtained is Perlegen's BrevaGen breast cancer risk test. In addition, it said that it acquired a suite of granted patents valid to 2022 that augment and extend its current non-coding patent portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.